Patents by Inventor Sandrine Moutel

Sandrine Moutel has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Synthetic single domain antibody
    Patent number: 11866484
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: March 3, 2021
    Date of Patent: January 9, 2024
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE), INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Single Domain Antibodies and Their Use in Cancer Therapies
    Publication number: 20230302050
    Abstract: The present application relates to fully humanized anti-FGFR4 single domain antibodies (sdAbs) and variants thereof. The present invention further relates to functionalized drug nanocarriers, nucleic acids, vectors, host cells, immune cells comprising said sdAbs, and compositions comprising thereof, as well as their use for therapy.
    Type: Application
    Filed: May 20, 2021
    Publication date: September 28, 2023
    Applicants: Institut Curie, Centre National de la Recherche Scientifique, The University of Zurich, Honing Biosciences
    Inventors: Sandrine Moutel, Franck Perez, Michele Bernasconi, Nagjie Laila Alijaj, Zélia Gouveia
  • Synthetic Single Domain Library
    Publication number: 20230183675
    Abstract: The present invention relates to the identification of a fully humanized single domain antibody scaffold as well as its use in generating synthetic single domain antibodies. The invention further relates to antigen-binding proteins comprising said single domain antibody scaffold and their use in therapy.
    Type: Application
    Filed: May 20, 2021
    Publication date: June 15, 2023
    Applicants: Institut Curie, Centre National de la Recherche Scientifique
    Inventors: Franck Perez, Sandrine Moutel
  • Synthetic Single Domain Antibody
    Publication number: 20210347855
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Application
    Filed: March 3, 2021
    Publication date: November 11, 2021
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Synthetic single domain antibody
    Patent number: 11014977
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: June 25, 2018
    Date of Patent: May 25, 2021
    Assignees: INSERM (Institut National de al Santé et de la Recherche Médicale), Institut Curie, Université Paus Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Anti-LSP1 antibody
    Patent number: 10968281
    Abstract: The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.
    Type: Grant
    Filed: October 13, 2017
    Date of Patent: April 6, 2021
    Assignees: INSTITUT CURIE, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE, INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MEDICALE
    Inventors: Elodie Segura, Sebastian Amigorena, Franck Perez, Sandrine Moutel
  • NEW ANTI-LSP1 ANTIBODY
    Publication number: 20190367635
    Abstract: The present invention provides a new anti-LSP1 (Leukocyte specific protein 1) antibody. This new antibody allows the specific staining of inflammatory dendritic cells and can be used in diagnosis methods or as a medicament when conjugated to a drug.
    Type: Application
    Filed: October 13, 2017
    Publication date: December 5, 2019
    Inventors: ELODIE SEGURA, SEBASTIAN AMIGORENA, FRANCK PEREZ, SANDRINE MOUTEL
  • Synthetic Single Domain Antibody
    Publication number: 20180327481
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2dAb) and its use in generating synthetic single domain antibody library (hs2dAb-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Application
    Filed: June 25, 2018
    Publication date: November 15, 2018
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Synthetic single domain antibody
    Patent number: 10030068
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: June 30, 2017
    Date of Patent: July 24, 2018
    Assignees: INSERM (Institut National de la Sante et de la Recherche Medicale), Institut Curie, Universite Paul Sabatier Toulouse III, Centre National de la Recherche Scientifique (CNRS)
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Synthetic single domain antibody
    Patent number: 10017559
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Grant
    Filed: November 4, 2014
    Date of Patent: July 10, 2018
    Assignees: INSERM (INSTITUT NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE, INSTITUT CURIE, UNIVERSITE PAUL SABATIER TOULOUSE III, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Aurellen Olichon, Sandrine Moutel, Franck Perez
  • Synthetic Single Domain Antibody
    Publication number: 20180030117
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Application
    Filed: June 30, 2017
    Publication date: February 1, 2018
    Inventors: Aurelien Olichon, Sandrine Moutel, Franck Perez
  • Synthetic Single Domain Antibody
    Publication number: 20160237142
    Abstract: The invention relates to the identification of a highly stable single domain antibody scaffold (hs2d Ab) and its use in generating synthetic single domain antibody library (hs2d Ab-L1). The invention also relates to antigen-binding proteins comprising said stable single domain antibody scaffold and their uses, in particular as therapeutics.
    Type: Application
    Filed: November 4, 2014
    Publication date: August 18, 2016
    Inventors: Aurellen Olichon, Sandrine Moutel, Franck Perez
  • Antibody specific for the Tn antigen for the treatment of cancer
    Publication number: 20100278818
    Abstract: The instant application provides a pharmaceutical composition comprising an antibody, directed against Tn antigen which comprises CDRs derived from 83D4 monoclonal antibody or an immunoconjugate of said antibody, said pharmaceutical composition being intended for the treatment of cancer.
    Type: Application
    Filed: June 19, 2008
    Publication date: November 4, 2010
    Applicant: INSTITUT CURIE
    Inventors: Pascale Hubert-Haddad, Sebastian Amigorena, Xavier Sastre, Eduardo Osinaga, Otto Pritsch, Pablo Oppezzo, Franck Perez, Sandrine Moutel